Skip to main content
. 2020 Jun 10;12(6):534. doi: 10.3390/pharmaceutics12060534

Figure 7.

Figure 7

Comparative release profiles (a) and plasma concentration–time curves (b) between the optimized FBX-SNELTs and marketed tablets.